Advertisement |
|
In the middle of innovation, medicine, growth, and so much more, Destination Medical Center (DMC) is transforming Rochester, MN. DMC is a 20-year, $5.6 billion economic development plan. Together, DMC and Mayo Clinic are accelerating new advancements in life science research, medical technology, patient care, and education. | | | |
|
|
TABLE OF CONTENTS |
March 2017 Volume 35, Issue 3 |
| | |
| In This Issue Editorial News Bioentrepreneur Opinion and Comment Features News and Views Research Careers and Recruitment
| | Advertisement | | | | Having trouble Immunophenotyping across multiple species?
Download our new infographic highlighting the power of profiling immune cell subsets across species. Visit FlowMetric at SOT2017, Booth #2608.
Download this Infographic now | | |
|
|
|
|
|
|
Advertisement |
|
Bioprocessing Technologies in Stem Cell Research: Challenges and Chances for Commercialization The 1st Stem Cell Community Day brings together experts from industry and academia to discuss recent achievements, challenges, and chances in stem cell bioprocessing for research and commercial manufacturing. Register now and submit your abstract! www.stemcellday.de | | | |
|
|
Advertisement |
|
|
|
|
Advertisement |
|
|
|
|
Advertisement |
|
|
|
|
|
| Focus on RNA-based therapies | | | A joint focus with Nature Reviews Drug Discovery on RNA-based therapeutics presents a series of articles detailing recent progress in chemistries and delivery technologies that have propelled the clinical advancement of oligonucleotide therapies as well as highlighting commercial advances in RNA vaccines. | |
|
|
In This Issue | Top |
|
|
|
In this issue ppvii - vii doi:10.1038/nbt.3831
|
|
Editorial | Top |
|
|
|
The commercial tipping point p181 doi:10.1038/nbt.3829 RNA-based therapeutics are poised to become successful commercial products, but wide adoption across the biopharmaceutical industry will likely take a few more years.
|
|
News | Top |
|
|
|
Billion-dollar deals end eras of Ariad and Actelion pp183 - 184 Melanie Senior doi:10.1038/nbt0317-183
|
|
|
|
CRISPR patents belong to Broad, says USPTO p184 doi:10.1038/nbt0317-184
|
|
|
|
Gender tokenism and bias prevail in biotech boardrooms pp185 - 186 Elie Dolgin doi:10.1038/nbt0317-185
|
|
|
|
Merck KGaA lands four Vertex cancer programs p186 doi:10.1038/nbt0317-186
|
|
|
|
Solithromycin rejection chills antibiotic sector pp187 - 188 Brian Owens doi:10.1038/nbt0317-187
|
|
|
|
Trump's pick rallies biosimilar makers p189 doi:10.1038/nbt0317-189b
|
|
|
|
Biogen pays Forward in Tecfidera dispute p189 doi:10.1038/nbt0317-189c
|
|
|
|
Celgene eyes 'inverse vaccines' in Anokion and Delinia deals pp189 - 190 Cormac Sheridan doi:10.1038/nbt0317-189a
|
|
|
|
New York spreads the news with $1.15 billion biotech plan p191 Gautam Naik doi:10.1038/nbt0317-191
|
|
|
|
Podcast |
|
|
|
First Rounders podcast: Stephen Quake p192 doi:10.1038/nbt.3808
|
|
|
|
Around the world in a month p192 doi:10.1038/nbt0317-192
|
|
|
|
News Features |
|
|
|
The 'anti-hype' vaccine pp193 - 197 Laura DeFrancesco doi:10.1038/nbt.3812 After years under the radar, RNA vaccines are finally emerging as immunotherapies to combat pandemics and cancer. But as Laura DeFrancesco reports, clinical validation remains elusive.
|
|
|
|
Worth the RISC? pp198 - 202 Ken Garber doi:10.1038/nbt.3810 The long, tortuous race to market a therapeutic based on RNA interference (RNAi) may be nearing its end. Ken Garber reports.
|
Advertisement |
|
Faster, Simpler Biological LC-MS/MS Analysis Shimadzu's Clinical Laboratory Automation Module, a fully integrated sample pretreatment module for LC-MS/MS, automatically performs all of the processes necessary for analyzing blood and other biological samples, providing more precise results by reducing human error and improving laboratory safety and efficiency. Learn more. | | | |
|
|
Bioentrepreneur | Top |
|
|
|
Data page |
|
|
|
Top US universities, institutes for life sciences in 2015 p203 Brady Huggett doi:10.1038/nbt.3818
|
|
Opinion and Comment | Top |
|
|
|
Correspondence |
|
|
|
US immigration order strikes against biotech pp204 - 206 Jeremy M Levin, Steven H Holtzman, John Maraganore, Paul J Hastings, Ron Cohen et al. doi:10.1038/nbt.3824
|
|
|
|
Why axing TPP was a lost opportunity for biotech pp206 - 207 Kevin E Noonan doi:10.1038/nbt.3821
|
|
|
|
Response to “Railroading at the FDA” pp207 - 209 Francesco Muntoni, Sue Fletcher and Steve Wilton doi:10.1038/nbt.3819
|
|
Features | Top |
|
|
|
Patents |
|
|
|
Evidence of insufficient quality of reporting in patent landscapes in the life sciences OPEN pp210 - 214 James A Smith, Zeeshaan Arshad, Hannah Thomas, Andrew J Carr and David A Brindley doi:10.1038/nbt.3809 Despite the importance of patent landscape analyses in the commercialization process for life science and healthcare technologies, the quality of reporting for patent landscapes published in academic journals is inadequate.
|
|
|
|
Recent patents in chimeric antigen receptors p215 doi:10.1038/nbt.3832
|
Advertisement |
|
|
|
|
News and Views | Top |
|
|
|
|
|
Research | Top |
|
|
|
Perspectives |
|
|
|
Overcoming cellular barriers for RNA therapeutics pp222 - 229 Steven F Dowdy doi:10.1038/nbt.3802 Recent progress in delivering RNA therapeutics to the inside of cells might lead to more success in clinical applications.
|
|
|
|
Cellular uptake and trafficking of antisense oligonucleotides pp230 - 237 Stanley T Crooke, Shiyu Wang, Timothy A Vickers, Wen Shen and Xue-hai Liang doi:10.1038/nbt.3779
|
|
|
|
Reviews |
|
|
|
The chemical evolution of oligonucleotide therapies of clinical utility pp238 - 248 Anastasia Khvorova and Jonathan K Watts doi:10.1038/nbt.3765 Refinements in the chemistries employed in oligonucleotide therapeutics have galvanized clinical progress. The complex interplay between chemical modifications and integration into sequence architecture is discussed in the context of antisense and small-interfering RNA drugs.
|
|
|
|
Oligonucleotide therapies for disorders of the nervous system pp249 - 263 Olga Khorkova and Claes Wahlestedt doi:10.1038/nbt.3784 Brain-targeted oligonucleotide-drugs are poised to treat multiple human central nervous system disorders with an emphasis on rare/orphan conditions.
|
|
|
|
Articles |
|
|
|
Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c pp264 - 272 Bifeng Pan, Charles Askew, Alice Galvin, Selena Heman-Ackah, Yukako Asai et al. doi:10.1038/nbt.3801 Gene therapy in the inner ear achieves unprecedented recovery of hearing and balance behavior in Usher syndrome mice.
See also: News and Views by Brigande
|
|
|
|
Dynamic regulation of metabolic flux in engineered bacteria using a pathway-independent quorum-sensing circuit pp273 - 279 Apoorv Gupta, Irene M Brockman Reizman, Christopher R Reisch and Kristala L J Prather doi:10.1038/nbt.3796 An inducer-free quorum-sensing circuit is applied to control endogenous bacterial gene expression and improve yields of a range of products.
|
|
|
|
Letter |
|
|
|
A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear pp280 - 284 Lukas D Landegger, Bifeng Pan, Charles Askew, Sarah J Wassmer, Sarah D Gluck et al. doi:10.1038/nbt.3781 Efficient gene transfer to the mouse inner ear is achieved with a synthetic adeno-associated viral vector.
See also: News and Views by Brigande
|
|
Careers and Recruitment | Top |
|
|
|
International mentoring as a new educational approach to alleviate brain drain, empower young talent, and internationalize higher education pp285 - 288 Maria Soriano-Carot, Rosa Breton-Romero, Joaquin Lopez-Herraiz, Rocio Lopez-Diego, Abel Suarez-Fueyo et al. doi:10.1038/nbt.3822 A novel program shows that young professionals working abroad can be instrumental in their home country's development.
|
|
|
|
People |
|
|
|
People p290 doi:10.1038/nbt.3830
|
Advertisement |
|
nature.com webcasts Circulating Tumour Cells: Liquid biopsy by high-throughput, high-resolution imaging flow cytometry Date: Tuesday, March 28, 2017 Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST Register for FREE Sponsored by: Merck KGaA, Darmstadt, Germany. he life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada | | | |
|
|
| | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | |
|
|
No comments:
Post a Comment